JULY 2026
VOL. 15 | ISSUE 07

THE NUTRA ECONOMIST

nutrify today

INTELLIGENCE • INNOVATION • IMPACT

CONTENTS

The New Battleground for Preventive Health

Why pharma and consumer giants are converging on wellness—and why trust is becoming the industry's most valuable asset.

SPECIAL REPORT

GENIE™
Nutra Innovation Partner

WORLD'S LARGEST AI POWERED NUTRACEUTICAL DATABASE

For Faster, Smarter Nutra Innovation, Responsibly !



How can companies leverage this Intelligence ?

GenEI™	ConcierGENIE™	NutrifyAI™
Discover. Innovate. Launch DIY modules with annual subscription - based access to datasets	**White Glove Innovation** White Glove Innovation From concept to finished products in your warehouse, your NI partner all the way	**Ask & Seek the Nutraverse** Prompt based accurate responses from the curated Genie Dataset

NuToday India Pvt. Ltd. **Reach out to us with your queries on hello@nutrifytoday.com**

nutrify today - SUITE®

Networthing the Networks

1:1 DEAL MAKING

CURATED PANELS

INNOVATION SHOWCASE

REGULATORS
DECISION MAKERS
INVESTORS
INDUSTRY SHAPERS
FOUNDERS
MANUFACTURERS
INNOVATORS
AND MORE..

GLOBAL TRENDS

300+ GLOBAL CXOS

The Definitive Nutra Forum

DEAL-MAKING. LEARNING. PROBLEM SOLVING

2027

INVITE-ONLY I DECISION-GRADE

MUMBAI

Supported By

वाणिज्य एवं उद्योग मंत्रालय
MINISTRY OF COMMERCE AND INDUSTRY

MOFPI
MINISTRY OF FOOD PROCESSING INDUSTRIES
GOVERNMENT OF INDIA

INDIA CHAMBER
INDIA CHAMBER OF BUSINESS AND COMMERCE

https://nutrifycsuite.com/

MAGAZINE INDEX

THE NUTRITION ECONOMY IS ENTERING ITS INSTITUTIONAL AGE

PRIYANKA SRIVASTAVA

Chairperson, NutrifyToday

Trust, evidence and organisational capability not product proliferation will determine the next generation of global nutrition leaders.

The global nutrition industry is no longer defined simply by the sale of vitamins, powders, capsules or gummies. It is being reshaped by a more consequential contest: who can earn the right to participate repeatedly in a consumer's health decisions?

That right is built on trust.
The reported multibillion-dollar interest in Thorne, accelerating acquisition activity across India's nutraceutical sector, the emergence of evidence-led opportunities in Brazil and growing scrutiny of wellness claims all point to the same conclusion. Formulations can be copied. Formats can be imitated. Influencer campaigns can be outspent. What cannot be assembled quickly is a durable institution of scientific credibility, manufacturing quality, professional advocacy, regulatory discipline and consumer confidence.

This is the central economic shift examined in this issue of NutraEconomist.
Preventive health is becoming a daily operating system. Consumers are no longer purchasing nutrition products only to correct a deficiency or support recovery.

They are using them to manage sleep, stress, digestion, cognition, appearance, metabolic health, athletic performance and healthy ageing. This broadening of use creates enormous commercial opportunity, but it also raises the standard of responsibility. The industry is moving closer to health management while many of its products continue to be marketed with the evidentiary habits of fast-moving consumer goods.

That tension will define the next decade.
India illustrates both the promise and the risk. Strategic buyers from pharmaceuticals, consumer goods, food and beauty are converging on nutraceutical platforms. Digital-first brands have proved that sharply defined need states, attractive formats and omnichannel distribution can create meaningful enterprise value. Yet brand growth alone does not create a health institution. The deeper moat will come from finished-product evidence, proprietary formulations, repeat economics, practitioner trust, robust quality systems and the patience to build categories that cannot be replicated with a contract manufacturer and a media budget.

This is why clinical nutrition may become one of India's most important undercapitalised opportunities. Oncology, metabolic health, sarcopenia, women's health and disease-related malnutrition offer substantial unmet need. They also demand longer research cycles, hospital partnerships, specialist manufacturing, conservative claims and patient capital. The difficulty is not a disadvantage; it is the source of defensibility.

Brazil presents a related lesson. Its wellness economy is already large, but the investable opportunity is not "more supplements" in the abstract. It lies in precise segmentation by age, life stage and health need. Muscle longevity, metabolic support, women's health, gut health and clinically coherent botanical innovation can become major platforms. However, the winners will need to combine affordability and local relevance with testing, traceability, responsible claims and hybrid distribution through pharmacies, healthcare professionals and digital channels.

At the same time, the industry must confront its habit of turning uncertain biology into marketable numbers. Eight hours of sleep, 10,000 steps and the latest fashionable supplement can be useful reference points, but they are not universal biological commandments. When population guidance becomes an individual mandate, fear becomes a sales tool. The better future for wellness is not number-free; it is number-wise. Guidelines should act as guardrails, while personal observation, clinical investigation and measurable outcomes determine what works for the individual.

Behind every credible brand is another institution that receives too little attention: the organisation that makes the product. Manufacturing plants, laboratories and certifications matter, but reliability ultimately comes from people making correct decisions consistently. Human resources, training, ethical culture, inclusion, leadership development and shop-floor discipline are not administrative matters in a CDMO. They are components of product quality and customer trust.

The nutrition economy is therefore entering its institutional age. The next generation of leaders will not be judged only by revenue growth, funding rounds, acquisitions or SKU counts. They will be judged by what remains valuable when advertising slows, founders step back and formats lose their novelty. The enduring assets will be evidence, quality, data, talent, governance, professional confidence and consumer trust.

NutraEconomist will continue to examine this transition through a clear economic and scientific lens: growth deserves attention, but durable health value demands scrutiny. The companies that turn proof into trust, trust into habit and habit into better outcomes will not merely build successful brands. They will build the institutions that define the future of global nutrition.

THE NEW BATTLEGROUND FOR PREVENTIVE HEALTH

Thorne's reported sale and India's nutraceutical deal wave reveal why trust—not formulations—is becoming the most valuable asset in wellness.

NUTRIFYTODAY EDITORIAL TEAM

A potential $4 billion auction for a supplement company might once have looked like market exuberance. Today, it looks more like a strategic land grab.

Thorne, the U.S. science-led nutrition company acquired by L Catterton for $680 million in 2023, is expected to generate about $650 million in 2026 revenue. A sale at the reported upper valuation would imply roughly 6.2 times sales and nearly six times its take-private price three years ago. Reuters has reported that Haleon submitted a bid, while other global consumer groups have been linked to the process.

The bidders are not simply competing for magnesium, omega-3, and multivitamin products. Those formulations can be replicated. They are competing for something harder to build: scientific credibility, manufacturing quality, practitioner advocacy, premium brand permission, and recurring consumer relationships.

Call it the "trust stack." It is becoming the strategic asset in preventive health.

From Supplements to Daily Health Management

Grand View Research estimated the U.S. dietary-supplement market at $68.7 billion in 2025 and projected it to reach $131.1 billion by 2033—annual growth of about 8.4%. CareEdge Ratings estimates India's broader nutraceutical market, including supplements, functional foods, and functional beverages, at $29 billion to $30 billion, with the potential to reach $55 billion to $57 billion by 2030. That implies growth of roughly 11% a year.

The estimates are not directly comparable because the Indian definition is wider. But they reveal the same behavioral shift: consumers are moving from episodic treatment toward continuous health management.

They are buying products for sleep, stress, digestion, immunity, glucose management, cognition, appearance, athletic performance, and healthy aging. As wearables, diagnostics, and personalized recommendations spread, preventive health is becoming a daily routine rather than an occasional purchase. That changes the unit of competition. The winner is no longer the company with the most products. It is the company that earns the right to participate repeatedly in a consumer's health decisions.

Supplements remain a high-information-asymmetry category. Most consumers cannot independently assess dosage, bioavailability, contamination risk, clinical relevance, or whether research on an ingredient applies to the finished product. In this market, trust becomes economic infrastructure.

Thorne's practitioner heritage, scientific positioning, quality controls, and direct consumer relationships reduce perceived risk—the source of its strategic premium. A formulation can be reverse-engineered. An institution of trust cannot.

India Is Building the Platform from Several Directions

India's transaction landscape shows the preventive-health platform being assembled by several industries converging on the same consumer.

Hindustan Unilever's decision to pay ₹824 crore for the remaining 49% of OZiva is one example. HUL reported that OZiva had reached approximately ₹480 crore in 2025 revenue after delivering a two-year compound growth rate of about 130%. At the same time, HUL sold its 19.8% stake in Wellbeing Nutrition for ₹307 crore.

Together, the moves indicate a shift from experimentation to concentration around the platform HUL believes it can scale. USV's agreement to acquire 79% of Wellbeing Nutrition, at a valuation of approximately ₹1,583 crore, illustrates movement in the opposite direction.

A prescription-led pharmaceutical company is acquiring a digital-first wellness relationship. USV contributes medical credibility and therapeutic expertise; Wellbeing contributes consumer data, modern formats, omnichannel distribution, and participation in everyday prevention.

Sun Pharma's agreement to acquire Innovcare Lifesciences for ₹271.2 crore reinforces the pattern. Innovcare generated ₹94.06 crore in fiscal 2026 revenue, implying a transaction value of about 2.9 times sales. Its portfolio spans pharmaceuticals, nutraceuticals, functional foods, and cosmeceuticals—the categories where treatment, prevention, and appearance-related health increasingly overlap. Cipla's acquisition of pediatric and wellness company Inzpera points in the same direction.

Pharma is consumerizing, while consumer goods are medicalizing. Nutraceuticals are where they meet.

Other transactions are erasing the boundaries among food, beauty, and health.

Tata Consumer's ₹1,900 crore acquisition of Organic India added herbal supplements, teas, organic sourcing, and international reach. Marico's agreement to acquire 60% of Cosmix, at an equity valuation of approximately ₹375 crore, added plant protein and functional nutrition.

Honasa Consumer's move to acquire 58% of Fluence Pharma, at an enterprise value of about ₹135 crore, connects ingestible nutrition with dermatology and "inside-out" beauty.

These are not random adjacencies. Consumers increasingly define health around outcomes, not industry categories. A food, beauty product, supplement, and medicine may all compete to deliver better sleep, healthier skin, metabolic support, or greater energy.

The Infrastructure Behind the Brand

A fourth trend is less visible: capital is moving into the manufacturing infrastructure behind wellness brands.

Kotak Alternate Assets' ₹1,050 crore investment in Tirupati Medicare reflects the value of formulation expertise, dosage innovation, regulatory compliance, quality systems, and export capacity. As the category scales, brand promises will be only as credible as the systems producing the product.

This creates two layers of value: consumer-facing trust platforms and the contract developers and manufacturers that serve as their quality backbone.

India has a particular opportunity at this second layer. Its pharmaceutical manufacturing experience, botanical knowledge, formulation talent, and cost-efficient production could make it both a major wellness market and a global innovation and supply base.

The U.S. Is Pricing the Platform; India Is Assembling It

The United States is further along in premiumization and consolidation. Thorne represents a relatively integrated platform: science, practitioner credibility, quality systems, direct commerce, personalization, and premium positioning under one brand.

India is assembling similar capabilities across multiple owners. Consumer companies contribute distribution and category creation. Pharmaceutical companies contribute medical credibility and access to doctors and pharmacies. Digital-native brands contribute speed and consumer data.

Ayurveda and botanical businesses contribute cultural legitimacy. Manufacturers contribute quality and scale.

India is also developing two markets simultaneously. Premium preventive wellness is driven by digital discovery, specialized formulations, and affluent urban consumers. Mass preventive nutrition is built around familiar foods, beverages, traditional ingredients, affordability, and broad retail access.

That dual-market structure may become India's distinctive advantage. A global platform could combine Western clinical and brand authority with Indian botanical supply chains, formulation capabilities, manufacturing economics, and insight into value-conscious consumers.

What Acquirers Must Get Right

Not every deal will create value. Distribution can increase availability, but it cannot manufacture credibility. Growth can conceal weak retention, high customer-acquisition costs, replicable formulations, excessive discounting, or claims that will not withstand scrutiny.

Acquirers should test six things separately: finished-product evidence, manufacturing control, repeat purchase without heavy promotion, durable practitioner relationships, regulatory defensibility, and the brand's permission to enter adjacent health needs.

Integration requires restraint. A large owner can destroy a premium wellness brand through uncontrolled SKU expansion, short-term promotions, or exaggerated claims. Scientific credibility must be managed as operating infrastructure, not marketing copy. Thorne's eventual owner will attract headlines. But the larger shift is already clear. Preventive health is becoming an operating system cutting across pharmaceuticals, consumer goods, food, beauty, diagnostics, and technology.

The United States is showing what a mature trust platform may be worth. India is showing how the next generation may be built. The winners will not be the companies with the most pills, powders, or gummies. They will be the companies that turn proof into trust, trust into habit, and habit into a durable global health franchise.

Brazil's
Wellness Market

BRAZIL'S WELLNESS MARKET IS LARGE. THE INVESTABLE OPPORTUNITY IS EVIDENCE-LED NUTRITION

An aging population, worsening metabolic health, and a mainstream fitness culture are creating a supplement market worth approximately R$25–30 billion. The winners will segment by life stage, build clinical trust, and resist selling undifferentiated pills.

NUTRIFYTODAY EDITORIAL TEAM

Brazil is already a global wellness power. Its wellness economy was valued at approximately US$125 billion in 2024, equivalent to nearly R$676 billion at the year's average exchange rate. This makes Brazil the largest wellness market in Latin America and one of the 12 largest globally.

The headline size, however, needs careful interpretation. Between 2019 and 2024, Brazil's wellness economy grew much faster in local currency than in US-dollar terms, partly reflecting exchange-rate depreciation. Wellness spending also declined slightly as a proportion of national GDP. Brazil therefore offers enormous scale and strong domestic-market momentum, but it should not be approached as an indiscriminate category boom.

The opportunity is concentrated in specific demographic and health transitions.

The Demand Engine Is Demographic and Medical

Brazil's population is growing slowly, but its age structure is changing rapidly.

In 2024, the country had approximately 34 million people aged 60 and above. By 2030, this population is expected to exceed 41 million—an increase of more than 20% in just six years. Over the same period, the population aged 18–29 is projected to contract.

The largest consumer cohort today is the 30–44 age group, with approximately 49 million people. The 45–59 cohort is also expanding and is likely to become increasingly important for preventive health, weight management, hormonal health, cardiovascular support, mobility, and healthy aging.

Older consumers should not automatically be treated as economically dependent. Approximately one in four Brazilians aged 60 and above remains employed. Average employment income among working older adults is also higher than the national average for all workers.

This creates a two-speed opportunity.

Consumers aged 30–44 represent the largest aggregate wallet today. They are actively spending on fitness, appearance, productivity, weight management, parenting, and preventive health.

Consumers aged 60 and above offer the strongest structural growth and the greatest health-need intensity. Their spending is likely to be directed toward mobility, cognition, bone health, muscle preservation, cardiovascular health, digestive health, sleep, and chronic-disease support.

The medical context makes this demographic transition even more important.

Diagnosed diabetes among adults in Brazilian state capitals has more than doubled since 2006. Obesity prevalence has risen sharply, more than 60% of adults now live with excess body weight, and diagnosed hypertension affects close to 30% of the adult population.

Physical activity has improved in some segments, particularly leisure-time exercise. Yet this has not been sufficient to reverse the metabolic-health trajectory.

Brazil therefore presents a distinctive market combination: a sophisticated fitness and beauty culture existing alongside a rapidly worsening burden of obesity, diabetes, hypertension, and age-related health decline.

This is precisely the environment in which nutritional supplements can grow—but only when positioned as support for better nutrition, physical activity, and medical care rather than as substitutes for them.

The Supplement Market Is Approximately R$25–30 Billion

The broader Brazilian healthy-eating, nutrition, and weight-management economy is estimated at approximately US$35–36 billion. Vitamins and dietary supplements account for an estimated 13–15% of this category.

A second, country-level market estimate places Brazil's dietary-supplement market at approximately US$4.6 billion in 2024, with projected annual growth of close to 10% through 2030.

Triangulating these estimates suggests that Brazil's broad supplement market is currently worth approximately US$4.6–5.5 billion, equivalent to R$25–30 billion.

This includes vitamins, minerals, botanicals, proteins, amino acids, collagen products, omega oils, probiotics, fibers, sports-nutrition products, and other functional nutrition formats.

Supplements therefore represent approximately 4% of Brazil's total wellness economy and around 13–15% of its healthy-eating and weight-management market.

Consumer penetration is already significant. A survey across major Brazilian cities found at least one supplement consumer in nearly six out of ten households. While this should not be interpreted as a current national prevalence rate, it demonstrates that supplementation has moved far beyond athletes and affluent wellness enthusiasts.

It is becoming a mainstream household behaviour.

Which Age Groups Drive the Market?

Brazil does not publish a definitive audited breakdown of wellness expenditure by age. However, a strategic allocation based on population size, purchasing power, health needs, fitness participation, and preventive-health behaviour provides a useful view of market potential.

The 30–44 cohort is likely to represent the largest aggregate supplement pool, with an estimated annual market value of approximately R$7–8 billion. This group combines income, digital adoption, appearance consciousness, fitness participation, parenting responsibilities, and growing concern about long-term health.

The 45–59 cohort may account for another R$6–7 billion. This is arguably Brazil's most underappreciated supplement segment. These consumers are beginning to experience changes in metabolism, sleep, muscle mass, hormonal balance, blood glucose, joint comfort, cardiovascular risk, and energy. They are often willing to spend but demand greater credibility than younger consumers.

The 60-plus market may already be worth R$5–6.5 billion. Although smaller in total population than the middle-aged cohorts, it has the highest estimated per-capita supplement intensity. It will also be the fastest-growing major demographic segment over the next decade.

The 18–29 cohort likely contributes R$4.5–5.5 billion. Younger adults remain critical cultural accelerators. They drive sports nutrition, social-commerce discovery, creator-led brands, beauty supplements, energy products, and innovative formats. But they should not automatically be assumed to hold the largest wallet.

Children and adolescents represent a smaller but still meaningful market, largely mediated through parental purchasing. Opportunities exist in paediatric nutrition, immunity, cognition, growth, and deficiency correction, although regulation, dosing, safety, and medical oversight are particularly important.

The strategic conclusion is clear: Brazil should not be treated as one supplement consumer market. It is at least five overlapping markets, each defined by different motivations, health concerns, channels, and trust requirements.

Four Supplement Bets Stand Above the Rest

1. Muscle Longevity, Not Just Sports Nutrition
Proteins and amino acids are expected to be among Brazil's fastest-growing supplement segments.

The larger opportunity is not limited to gym users. A single muscle-health platform can serve a 25-year-old seeking strength, a 45-year-old trying to preserve body composition, and a 70-year-old seeking mobility and independence.

Protein, creatine, amino acids, vitamin D, magnesium, and other supportive nutrients can be adapted across these populations. The formulation may remain similar, but the messaging, format, flavour, dose, and distribution channel should differ.

Brands that continue to position muscle health only through bodybuilding imagery risk missing the much larger longevity market.

2. Metabolic Health and GLP-1 Companion Nutrition
Brazil's obesity and diabetes trajectory makes metabolic health one of the most attractive opportunities.

The weak proposition is another unsubstantiated "fat burner."

The stronger proposition is a structured nutritional-support platform for people managing obesity, insulin resistance, pre-diabetes, diabetes, or medically supervised weight loss.

The rapid adoption of GLP-1 medicines creates a new companion-nutrition market. Users may face reduced appetite, gastrointestinal discomfort, lower nutrient intake, dehydration, loss of lean mass, and difficulty maintaining long-term dietary quality.

An evidence-led platform could combine protein, fiber, hydration support, micronutrients, resistance-training guidance, dietitian access, and digital adherence monitoring.
The supplement should not be positioned as an alternative to medication. It should be positioned as nutritional infrastructure surrounding medical weight management.

3. Women's Health Across Life Stages
Women's health should not be treated as a single category. Brazil offers opportunities across fertility preparation, prenatal nutrition, postpartum recovery, iron status, polycystic ovary syndrome support, perimenopause, menopause, bone health, muscle preservation, sleep, and healthy aging.

Prenatal supplementation is expected to remain a high-growth application, but menopause may become one of the most strategically important emerging categories.

The winning platform will follow women across life stages instead of selling isolated products. It will require clinically relevant formulations, healthcare-professional engagement, responsible claims, and strong education. Pink packaging around generic ingredients will not be enough.

4. Gut Health, Beauty-from-Within, and Brazilian Botanicals
Gut health, skin health, and natural ingredients are well aligned with Brazilian consumer preferences.

However, these categories are increasingly crowded and vulnerable to weak differentiation.

The strongest opportunities are likely to emerge from strain-specific probiotics, clinically meaningful prebiotic-fiber doses, microbiome-linked metabolic products, collagen and skin-health products with measurable endpoints, and standardized botanical ingredients with traceable sourcing.

Brazilian biodiversity can become a global competitive advantage, but only when companies invest in standardization, safety, benefit-sharing, sustainability, and scientific substantiation.

A native ingredient is not automatically an innovation. It becomes an innovation when its chemistry, mechanism, dosage, quality, safety, and clinical relevance are clearly established.

Trust Will Be the Operating Model

Brazilian supplement regulation permits only authorized ingredients and establishes minimum and maximum levels for different population groups. Products cannot legally claim to prevent, treat, or cure disease.

Regulatory discipline should therefore be viewed as a commercial advantage rather than a compliance burden.
The strongest brands will invest in independent testing, batch traceability, transparent Portuguese-language labelling, clinically relevant dosages, stability testing, and disciplined claims.

Pharmacies will remain critical because consumers associate them with authenticity, professional guidance, and safety.
E-commerce will continue to grow through convenience, subscription models, price comparison, personalised recommendations, and automatic replenishment.

The optimal model is likely to be hybrid: acquire trust through pharmacists, physicians, nutritionists, gyms, and healthcare channels, then use digital platforms to support retention, education, personalisation, and repeat purchases.

Affordability will also matter. Brazil's income distribution makes a good-better-best portfolio architecture essential. Premium clinical brands may succeed among affluent consumers, but mass-market growth will require accessible formats, monthly affordability, and credible value per dose.

The Real Opportunity

Brazil does not primarily need more supplement SKUs.
It needs sharper segmentation, stronger evidence, better formulations, responsible claims, and more effective adherence models.

The most attractive businesses will connect formulation platforms to clearly defined life stages. They will build trust through healthcare professionals and pharmacies while using digital channels for personalisation and continuity.
They will avoid competing only on ingredient lists, celebrity endorsements, and discounts.

Brazil's wellness economy is already large. Its supplement market is already mainstream. The next phase will be defined not by how many products companies launch, but by how precisely they solve health needs, how credibly they substantiate their promises, and how successfully they remain part of consumers' lives over time.

The opportunity is not simply to sell more capsules.
It is to build the nutritional infrastructure for a country that is becoming older, more health-conscious, more digitally connected and more metabolically vulnerable.

Data sources used for market triangulation include IBGE, Brazil's Ministry of Health, Anvisa, the Global Wellness Institute, ABIAD, and international supplement-market research databases.


ibSium®
S. cerevisiae CNCM I-3856
ibSium®:
THE CLINICALLY PROVEN BIOTIC YEAST FOR EFFECTIVE IBS SYMPTOMS MANAGEMENT
Backed by Four Studies & a Meta-analysis
DISCOVER MORE ON
www.gnosisbylesaffre.com
Gnosis
by Lesaffre

DEBUNKING SLEEP: THE 8–8–8 POLITICAL SLOGAN, THE ALZHEIMER'S HEADLINE, AND THE BUSINESS OF SELLING US A NUMBER

Eight hours was once a demand for a humane working life. It was never a biological warranty. The trouble begins when a useful population range becomes an individual commandment and then a shopping category.

NUTRIFYTODAY EDITORIAL TEAM

The number eight has enjoyed an extraordinary career.

Eight hours for work. Eight hours for recreation. Eight hours for rest. Then, gradually, "eight hours of sleep" became not merely a recommendation but a test of whether one was living correctly. Sleep less and you are damaging your brain. Sleep more and, according to the latest headline, perhaps Alzheimer's disease is approaching.

Having first made people anxious about not reaching eight, are we now going to make them anxious about exceeding it?

This is how wellness marketing thrives: convert uncertain, probabilistic biology into a memorable number; convert that number into a target; convert failure to meet the target into fear; and then sell a device, supplement, app or programme to close the gap.

The problem is not sleep science. The problem is sleep numerology.



Exhibit one: 8–8–8 was political arithmetic, not sleep physiology

The famous formulation "eight hours labour, eight hours recreation, eight hours rest" came from the nineteenth-century campaign for the eight-hour working day. Robert Owen proposed the eight-hour day in 1817, and the slogan later became part of labour movements seeking protection from punishingly long working hours. It was a political and social demand: workers required time outside the factory to recover, learn, participate in family life and remain citizens rather than merely units of production. It was not derived from brain-wave recordings, circadian biomarkers or randomized sleep experiments.

"Eight hours rest" also did not necessarily mean eight hours of uninterrupted, laboratory-defined sleep. Rest included the non-working portion of life.

But we should not replace one simplistic story with another. Modern sleep recommendations were not merely copied from a trade-union banner. Contemporary guidance draws on epidemiology, laboratory studies, clinical experience and expert consensus. Significantly, that guidance generally describes ranges, not an exact eight-hour prescription. The CDC advises at least seven hours for adults aged 18–60, seven to nine hours for ages 61–64, and seven to eight hours for adults aged 65 and older. Other sleep-health guidance similarly places most healthy adults within a broad seven-to-nine-hour range while recognising individual variation.

So eight hours is not scientific nonsense. It is approximately the middle of a useful population range.

The distortion occurs when the midpoint is marketed as a mandate.

Exhibit two: what the Alzheimer's study actually found

The Medical News Today headline is carefully worded: sleeping longer than 8.5 hours may be a sign of Alzheimer's disease. Unfortunately, what many readers will remember is something much cruder:

More than 8.5 hours of sleep causes Alzheimer's.

That is not what the study showed.

The research involved 2,410 participants in the Framingham Heart Study, whose average age was approximately 70. Participants reported their usual sleep duration, and researchers examined blood levels of several biomarkers, including phosphorylated tau-181, or p-tau181, which is associated with Alzheimer's-related pathology. Using a nonlinear statistical model, the researchers found higher p-tau181 levels among people reporting approximately 8.5 hours or more of sleep, with a more pronounced rise at very long durations.

That sounds dramatic until we inspect the machinery.

First, this was a cross-sectional snapshot. Sleep duration and biomarker levels were measured around the same period. The study therefore cannot establish which came first.

It did not randomly assign people to sleep for seven, eight or ten hours and then observe who developed Alzheimer's disease. It cannot demonstrate that longer sleep produced the biomarker change.

Long sleep may be the smoke rather than the firewood. Early neurodegenerative changes could alter sleep regulation, increase fatigue, fragment sleep or extend the amount of time people spend in bed. The authors themselves describe longer sleep as a possible behavioural marker of early neurodegenerative processes—not as established evidence that sleep is causing those processes.

Second, sleep duration was self-reported. People are not precision sleep instruments. Time in bed is not necessarily time asleep, and a person reporting ten hours may actually be experiencing repeated awakenings, poor sleep quality, sleep apnoea, pain or prolonged periods lying awake.

Third, the alarming 8.5-hour point was not a biological cliff discovered in the brain. It was an estimated bend in a restricted cubic spline, a statistical technique designed to identify nonlinear relationships. When the researchers instead compared conventional sleep categories six hours or less, more than six but under nine, and nine hours or more the adjusted categorical comparisons did not show a significant association.

That does not invalidate the nonlinear result. It means the apparent threshold is model-dependent and requires replication, not that humanity has discovered an 8.5-hour Alzheimer's speed limit.

Fourth, the researchers measured several biomarkers. After fuller adjustment, p-tau181 was the principal signal that remained; relationships involving the other markers were less robust, and kidney function attenuated many of them. A recent systematic review cited alongside this work found heterogeneous results across studies, many null findings and substantial limitations from cross-sectional designs and differing sleep measurements.

The responsible interpretation is therefore:

A persistent increase in sleep duration among an older adult may be clinically informative and worth investigating.

The irresponsible interpretation is:

Set an alarm for 8 hours 29 minutes to protect yourself from Alzheimer's disease.

A 72-year-old who has recently moved from seven hours of refreshing sleep to ten hours of unrefreshing sleep presents a potentially meaningful change. A healthy person who has naturally slept eight-and-a-half or nine hours for decades is an entirely different proposition.

The seduction of the J-shaped graph

Sleep research frequently produces U-shaped or J-shaped relationships: poorer outcomes among short sleepers, the lowest apparent risk somewhere in the middle, and poorer outcomes again among long sleepers.

Such graphs invite an easy story: too little is dangerous, too much is dangerous, and the exact quantity in the centre must therefore be optimal. But the two ends of the curve need not have the same explanation.

At the short end, people may be actively restricting sleep because of work, caregiving, stress or insomnia. At the long end, additional sleep may reflect underlying illness, depression, medications, reduced activity, sleep fragmentation or early neurological change. Even careful statistical adjustment cannot eliminate every unmeasured difference between these groups.

This is why the article should not make people frightened of sleeping. It should make clinicians and researchers interested in changes in sleep need, sleep quality and daytime function.

The CDC explicitly distinguishes sleep quantity from sleep quality: repeated waking and remaining tired despite apparently sufficient hours are signs that the sleep may not be restorative.

Counting hours without asking how those hours were experienced is like measuring a restaurant by the number of minutes spent at the table rather than by what was served.

Exhibit three: the 10,000-step precedent

The 10,000-step target illustrates how easily a commercially memorable number becomes public-health scripture.

The target emerged from Japanese pedometer marketing in the 1960s rather than from a trial identifying 10,000 as a universal biological threshold. Subsequent research has confirmed that walking more is generally beneficial—but it has not confirmed that benefits suddenly begin at step 10,000.

In a study of older women, approximately 4,400 steps per day was associated with lower mortality than approximately 2,700, with the observed benefit levelling off at around 7,500 steps. A later meta-analysis found that the point at which mortality benefits levelled varied by age approximately 6,000–8,000 steps among older adults and 8,000–10,000 among younger adults.

The conclusion is not that 10,000 steps is harmful or that walking has failed. Ten thousand steps may be an excellent target for many people.

The conclusion is that 10,000 is not a metabolic border crossing.

A sedentary person progressing from 2,500 to 5,000 steps may obtain considerable benefit while technically "failing" the commercial target. An active person completing 11,000 slow steps is not necessarily metabolically protected from poor diet, loss of muscle mass, smoking, excessive alcohol, chronic stress or inadequate cardiovascular fitness.

Lifestyle diseases have not continued because walking is useless. They have continued because human health cannot be reduced to a single counter.

The same mistake is now being made with sleep: one number is asked to carry the weight of an entire biological system.

Exhibit four: magnesium glycinate and the supplement escalator

The supplement industry's preferred argument usually follows a recognisable sequence:

1. A nutrient participates in an important biological pathway.
2. Deficiency in that nutrient can produce symptoms.
3. Many people experience one of those symptoms.
4. Therefore, those people are probably deficient.
5. Therefore, a particular premium form of the nutrient is the solution.

Every step sounds plausible. The complete chain may still be unsupported.

Magnesium is an essential mineral involved in hundreds of biochemical processes. Low dietary intake occurs, and genuine deficiency deserves attention. But it does not follow that every person sleeping badly has magnesium deficiency—or that magnesium glycinate is a universal sleeping pill.

A 2025 randomized, double-blind, placebo-controlled trial did provide some form-specific evidence. It enrolled 155 adults reporting poor sleep and compared 250 mg of elemental magnesium as magnesium bisglycinate with placebo for four weeks. The supplement group experienced a statistically greater improvement in Insomnia Severity Index scores, but the effect was small—Cohen's d of approximately 0.2. Other psychological outcomes did not differ significantly, and the study did not use objective sleep measurements. Exploratory analysis suggested that participants with lower dietary magnesium intake might have responded better, but that subgroup finding needs confirmation.

That is not "magnesium does nothing."
It is also not "everyone needs magnesium glycinate before bed."

An earlier systematic review found only three randomized trials involving 151 older adults. Magnesium reduced reported sleep-onset time in the pooled analysis, but total sleep-time improvement was not statistically significant, and the authors judged the evidence too poor for firm clinical recommendations.

The accurate commercial message would therefore be: Magnesium may modestly help some people with poor sleep, possibly particularly those with inadequate intake, but the evidence remains limited.

That message does not fit neatly on a viral video.
The NIH recommends meeting nutritional needs primarily through food where practical. Green leafy vegetables, legumes, nuts, seeds and whole grains are important magnesium sources. It also sets an adult upper limit of 350 mg per day for magnesium from supplements and medicines—not magnesium naturally present in food. Impaired kidney function raises the risk of toxicity, and magnesium can interact with several medicines, including some antibiotics and osteoporosis drugs.

Personalization should therefore begin with the question "Is there a plausible nutritional gap?", not "Which fashionable compound should I buy?"

Three more sleep markets built from uncertainty

Melatonin: a biological clock signal turned into a bedtime sweet. Melatonin has legitimate uses, particularly in circadian-timing problems. But it has been repackaged as a generic sedative and placed into gummies with the cultural status of confectionery.

In one US analysis of 25 melatonin gummy products, 22 were inaccurately labelled; most contained more melatonin than declared. This is not merely a debate about whether the ingredient works. It is a basic question of whether consumers are receiving the dose printed on the package.

Blue-light glasses: A plausible mechanism in search of a guaranteed outcome. Light influences circadian timing. That fact is sound.

The leap from that fact to "these glasses will fix your sleep" is much less secure. A Cochrane review of 17 randomized studies involving 619 participants found little or no short-term benefit for computer-related eye strain, while evidence concerning sleep was inconclusive and of very low certainty.

Reducing excessive bright light at an appropriate time may help circadian alignment. That does not prove every product marketed as "blue-light blocking" produces a meaningful clinical benefit.

Sleep trackers: when the dashboard becomes the diagnosis
Consumer trackers can be useful for noticing broad patterns. But an estimate of "deep sleep" generated by a wrist device is not equivalent to laboratory polysomnography.

Clinicians have described orthosomnia: people becoming preoccupied with obtaining perfect tracker scores, sometimes distrusting how they feel because an algorithm declares that they slept badly. The pursuit of ideal sleep then creates anxiety that makes sleep more difficult.

The paradox is exquisite: a device purchased to reduce sleep anxiety becomes another reason to lie awake.

The defence: guidelines are not the enemy

It would be easy to conclude that all recommendations are manipulative and that everyone should simply "listen to the body."

That, too, can become a slogan.

Our bodily signals are real, but they are not infallible. Chronic sleep restriction can become subjectively familiar. Caffeine may conceal sleepiness. Alcohol can facilitate initial drowsiness while degrading later sleep. Depression, sleep apnoea, pain, medications and circadian misalignment can all affect what the body appears to be requesting.

Someone functioning on five hours may genuinely feel adapted while still experiencing impaired attention or metabolic consequences. Someone requesting ten hours may be expressing healthy individual variation—or signalling accumulated sleep debt, fragmented sleep or illness.
A body signal is data, not a verdict.

Circadian timing also varies among people. Some naturally become sleepy and alert earlier; others naturally run later. Genes contribute to these preferences, while light exposure, age, working hours, meal timing and social obligations influence how the clock is expressed. NIH guidance explicitly recognises that individual sleep–wake timing differs and that environmental signals such as light, darkness and caffeine interact with internal circadian clocks.

Personalization therefore means combining three forms of evidence:

Population evidence tells us the broad zone in which risk is generally lower.
Personal observation tells us how an individual functions within that zone.
Clinical investigation tells us whether an unusual pattern reflects individuality or an underlying disorder.

None should be used alone.

A disciplined way to identify your own biological clock

Finding one's bioclock is not a licence to declare, after three busy nights, "I am genetically a five-hour sleeper." Nor does it require purchasing a ring, a mattress subscription and six supplements.

A useful personal assessment can begin with a two-to-three-week observation period.

1. Give the body a fair opportunity
Maintain a reasonably stable wake time and provide sufficient time for sleep. Do not try to calculate natural sleep need during a week of flights, deadlines, illness or deliberate restriction.

Consistency matters because irregular weekday and weekend schedules can repeatedly shift the sleep–wake system. Official sleep-health guidance recommends keeping sleep and wake times broadly consistent and avoiding large meals and alcohol close to bedtime.

2. Track function, not only hours

Record bedtime, estimated sleep onset, awakenings, final waking, naps, caffeine and alcohol timing, medications, exercise and meal timing.

Then record the outcomes that matter:

- Was waking spontaneous or dependent on repeated alarms?
- Was there significant daytime sleepiness?
- Was concentration stable?
- Was a large weekend "catch-up" required?
- Was sleep refreshing?
- Was mood and physical energy reasonably consistent?

The CDC recommends this kind of sleep diary when sleep problems are being evaluated.

3. Treat wearables as trend detectors

A wearable may help reveal that bedtime is drifting or that sleep is consistently interrupted. Do not treat a nightly stage score as a laboratory diagnosis. The most important result is not whether an algorithm awarded 82 or 91, but whether the pattern corresponds with daytime health and performance.

4. Look for a range, not a magic number

Your result may be 7¼ hours, 8 hours, 8¾ hours or a range that changes with physical exertion, illness, age and accumulated sleep debt.

The objective is not to force the body to achieve eight. It is to find the sleep opportunity associated with stable alertness, minimal involuntary sleepiness, reasonable mood, good function and little need for compensatory weekend sleeping.

5. Investigate meaningful changes

A new, persistent shift toward nine or ten hours—particularly when accompanied by unrefreshing sleep, daytime sleepiness, loud snoring, gasping, morning headaches, cognitive change or impaired driving—should not be dismissed as "my body asking for more." It deserves assessment.

Equally, habitual short sleep accompanied by irritability, concentration problems, repeated caffeine dependence or weekend catch-up should not be romanticised as high performance.

Personalized nutrition must replace supplement-by-slogan

The next phase of wellness should not merely replace "everyone needs eight hours" with "everyone needs magnesium glycinate."

Personalized nutrition should ask:

- What does this person routinely eat?
- Is magnesium intake genuinely low?
- Are there gastrointestinal, metabolic or renal factors affecting nutrient status?
- Which medicines may alter magnesium levels or interact with supplementation?
- Is the problem sleep timing, sleep quality, insomnia, breathing disturbance, anxiety or nutritional insufficiency?
- What outcome would demonstrate that the intervention is actually working?

For many people, the sensible first move is not a capsule but a diet containing more legumes, nuts, seeds, whole grains and leafy vegetables. For others, a carefully selected supplement may be reasonable.

Where a supplement is tried, it should be treated as a small personal experiment: change one variable, define the desired outcome in advance, track it for a limited period, and stop when there is no meaningful benefit. "I bought it" is not evidence that it worked.

Meal timing also belongs in this conversation. Chrononutrition—the study of how eating patterns interact with circadian biology—is an emerging field with potential for more individually tailored interventions, but researchers explicitly caution that further studies are needed. Regular meal timing, avoiding habitual heavy late-night meals and aligning food intake more closely with the active part of one's day are more defensible starting points than pretending that one universal schedule suits every chronotype and occupation.

The verdict

Eight hours is neither a fraud nor a commandment.

The 8–8–8 slogan was a political demand for balance and dignity. Modern sleep science offers broad evidence-based ranges. The recent Alzheimer's research contributes an interesting observation: in an older cohort, very long self-reported sleep was associated with higher p-tau181 in a nonlinear model. It does not establish that sleeping beyond 8.5 hours causes Alzheimer's disease.

Long sleep can be a clue. It is not a conviction.

Ten thousand steps can be a motivating target. It is not a universal physiological threshold.

Magnesium glycinate may help a subset of people. It is not bottled sleep.

The deeper problem is our tendency to turn health into obedience: reach the number, close the ring, earn the score, swallow the product. We replace biological literacy with consumer compliance.

The better future is not number-free. It is number-wise. Use population guidelines as guardrails. Observe your own patterns. Identify your natural timing. Pay attention to regularity, restoration and daytime function. Investigate unexplained changes. Personalize nutrition around actual intake, health status and measurable response—not around the supplement currently dominating social media. Do not blindly chase eight hours.

Do not become frightened of eight-and-a-half.

Learn when your body becomes sleepy, when it naturally becomes alert, how much rest allows you to function well, and when a change in that pattern is trying to tell you something. The future of wellness should not be another universal slogan. It should be a disciplined conversation with our own biology.

BEYOND GUMMIES AND GROWTH CAPITAL

Who is building a supplement brand - and who is building a legacy in India?

India's supplement startups have proved that sharp need-state branding and omnichannel distribution can create valuable businesses. The next frontier is harder: finished-product evidence, medical nutrition and institutions designed to outlive the exit.

India's supplement market is no longer a fringe category defined by protein powders and generic multivitamins. It now spans sports performance, beauty, women's health, gut health, metabolic wellness, modern Ayurveda and disease-specific medical nutrition. New brands are entering quickly, strategic buyers are acquiring faster-growing platforms, and investors are searching for the next category leader.

Yet the apparent unity of the market is misleading. India does not have one nutraceutical startup industry. It has at least three different businesses: consumer wellness brands; performance and lifestyle nutrition platforms; and clinical or medical nutrition companies. They differ in science, regulation, distribution, capital requirements and the time needed to earn trust. Treating all three as variants of the same direct-to-consumer model creates bad strategy and often bad investing.

CENTRAL JUDGEMENT

The fastest commercial outcomes have come from brand, distribution and need-state marketing. The most valuable long-term companies will combine those strengths with proprietary formulations, finished-product evidence, clinical channels and measurable health outcomes.

A market growing faster than its evidence base

Industry estimates place India's broad nutraceutical market at roughly US$29-30 billion in 2024, with the potential to approach US$55-57 billion by 2030. Those numbers are attractive, but founders and investors should use them carefully. Functional foods and beverages account for most of the broad market, while dietary supplements represent a much smaller share. A startup selling capsules, sachets or gummies cannot credibly claim the entire nutraceutical economy as its addressable market.

The definition problem matters. India still lacks a consistently applied industry classification that cleanly separates supplements, functional foods, traditional products, medical nutrition and pharmaceutical adjacencies. Large top-down market numbers can therefore disguise a much narrower serviceable market, especially for premium urban brands dependent on digital acquisition.

AMIT SRIVASTAVA

Chief Catalyst, Nutrify Today
Member-Nutra Task Force
Office of PSA To Government of India

The regulatory direction is also changing. The Food Safety and Standards Authority of India has tightened expectations around health claims and the substantiation of product-specific benefits. Foods for Special Medical Purpose face an even higher burden where products are positioned for the dietary management of disease. This is a crucial inflection point: evidence is becoming a competitive asset rather than an optional appendix to marketing.

Where Indian supplement startups are concentrating

Most investment and entrepreneurial activity is clustered in categories where consumer intent is already visible, product development is relatively fast and digital marketing can generate early demand. The pattern is commercially rational, but it also explains why several segments are becoming crowded.

Segment	Illustrative companies	Why it works	Structural weakness
Sports nutrition and protein	HealthKart and MuscleBlaze, Fast&Up, Cosmix	Clear use occasion, repeat consumption, community distribution and observable performance goals	Commoditised ingredients, counterfeit risk and heavy dependence on trust and pricing.
Women's health, beauty and hormones	OZiva, Gynoveda, parts of Plix	High-intent problems such as hair fall, PCOS, fertility, menstrual health and weight management.	Congested formulas and the danger of making medical implications without finished-product evidence.
Modern Ayurveda and metabolic wellness	Kapiva and other contemporary Ayurveda platforms	Cultural familiarity, botanical differentiation and large chronic-health need states.	Standardisation, contamination control, reproducible dosing and clinical validation remain demanding.
Gut health and microbiome	The Good Bug and emerging probiotic or synbiotic brands	Recurring symptoms, strong consumer curiosity and potential for programmes, diagnostics and data.	Strain-specific evidence, shelf stability, exaggerated claims and limited Indian cohort data.
Convenience-led premium wellness	Wellbeing Nutrition, Plix, OZiva and format innovators	Gummies, melts, effervescents and sticks improve trial, adherence and visual appeal.	Format innovation is easy to imitate and rarely creates a scientific moat by itself.
Clinical and medical nutrition	Esperer Nutrition; Hexagon Nutrition as a mature benchmark	Serious unmet need, professional channels, protocol integration and stronger barriers to entry.	Long evidence cycles, hospital adoption, specialist manufacturing and patient-capital requirements.

What is working best in their favour

1. Owning a need state rather than an ingredient
The best-positioned startups do not sell isolated ingredients. They organise the proposition around a problem or desired outcome: protein for serious performance, support for PCOS and cycle management, a programme for bloating and constipation, or nutrition during chemotherapy. Need states improve search intent, content relevance, referrals and repeat potential. They also allow a brand to add diagnostics, consultations, adherence support and community around the product.
The same strength can become a regulatory weakness when the marketing implication exceeds the evidence. The closer the promise moves toward disease prevention, treatment support or measurable clinical improvement, the greater the need for a finished-product dossier rather than borrowed science on individual ingredients.

2. Using D2C for discovery and omnichannel for scale
Direct-to-consumer channels remain valuable for testing propositions, gathering first-party data and acquiring early adopters. They are no longer a sufficient moat. Large outcomes increasingly require modern trade, pharmacies, company-owned stores, gyms, practitioners, hospitals or institutional partnerships. HealthKart's physical retail network, Kapiva's offline expansion and the pharmacy logic behind strategic acquisitions all reflect the same lesson: digital channels discover demand; trusted physical and professional channels compound it.

3. Demonstrating repeat economics, not merely first-order growth
A supplement business can manufacture impressive gross merchandise value through discounting, affiliates and paid media while remaining economically fragile.

The more important measures are repeat purchase, cohort retention, contribution margin by channel, stock turns and the cost of sustaining growth after the initial novelty fades. Strategic buyers now look beyond a brand's social presence to determine whether it has a durable consumption habit and a path to profitable distribution.

4. Benefiting from active strategic-buyer demand
Indian and multinational groups have shown a willingness to buy wellness growth rather than build every proposition internally. HUL's investment in OZiva, USV's controlling acquisition of Wellbeing Nutrition, Marico's investments in Plix and Cosmix, and Tata Consumer's acquisition of Organic India demonstrate an active market for brands that have already validated consumer demand.

This gives founders and investors a credible liquidity route. It also creates a temptation to optimise the company for strategic portability rather than scientific depth.

5. Operating against genuine structural health demand
India's need is not an advertising invention. The country has more than 100 million people living with diabetes and more than 130 million with prediabetes. Anaemia remains widespread among women and children. Cancer incidence is substantial, while the population over 60 is projected to expand rapidly over the coming decades. The opportunity is therefore real and enduring. The unresolved question is whether startups will address these conditions through clinically credible interventions or use them mainly as marketing themes.

The opportunities India has not yet fully capitalised

The largest white spaces are not necessarily the easiest to market. They sit where unmet need is high, evidence requirements are demanding and distribution depends on more than digital advertising. That difficulty is precisely what can create durable value.

Opportunity	Unmet need	What creates defensibility
Clinical nutrition and FSMP	Oncology, renal disease, liver disease, perioperative care, wound healing, COPD, post-ICU recovery and disease-related malnutrition.	Clinical data, hospital protocols, specialist manufacturing, professional trust and health-economic proof.
Healthy ageing and sarcopenia	Muscle loss, frailty, mobility, falls, appetite, cognition, bone health and recovery after hospitalisation.	Longitudinal measurement, geriatric and physiotherapy channels, adherence programmes and outcome data.
Metabolic health with biomarkers	Affordable programmes for diabetes, prediabetes, obesity and fatty-liver risk that measure HbA1c, waist, glucose and durability.	Integrated diagnostics, nutrition, behaviour support and disciplined clinical claims.
Women's full lifecycle	Adolescence, anaemia, menstrual health, fertility, pregnancy, postpartum recovery, menopause, bone and muscle loss.	Stage-specific protocols, diagnostics, practitioner networks and long-term customer relationships.
Functional foods in familiar diets	Protein, fibre and micronutrient enrichment in daily Indian foods and beverages rather than another pill.	Habit integration, local taste, affordability, manufacturing know-how and mass-market distribution.
India-specific microbiome and botanical IP	Locally characterised strains, Indian cohort data, standardised extracts, bioavailability systems and validated combinations.	Patentable assets, licensing potential, B2B exports and defensible science beyond the consumer brand.
Evidence and quality infrastructure	Claims dossiers, specialist CROs, stability testing, batch verification, post-market surveillance and real-world evidence.	A picks-and-shovels layer that benefits as regulation, investor diligence and consumer scrutiny increase.

Why clinical nutrition is the strongest undercapitalised opportunity

Clinical nutrition is not attractive because it is fashionable. It is attractive because the barriers are real. A credible company must develop clinically coherent formulations, build regulatory dossiers, work with hospitals and dietitians, manage taste and tolerance in vulnerable patients, and measure outcomes that matter to treatment pathways. These requirements slow growth, but they also reduce the ease with which a contract manufacturer and a social-media budget can reproduce the business.

The category can also expand beyond product revenue. A mature medical-nutrition platform can generate protocol partnerships, institutional contracts, licensing income, data assets and pharmaceutical collaborations.

Hexagon Nutrition illustrates the institutional potential of combining premixes, clinical products, therapeutic nutrition, exports and B2B relationships. Esperer Nutrition represents a younger, more focused attempt to build condition-specific portfolios, particularly in oncology.

Is the venture-capital-to-conglomerate-sale route the only template?

No. But for a broad consumer wellness brand, it is often the default template - and for understandable reasons. The early assets of such a company are usually brand recognition, digitally acquired consumer cohorts, repeat-purchase data, content capability and a portfolio that can be placed into a larger distribution system. An FMCG or pharmaceutical group already has procurement, manufacturing leverage, working capital, retail access and compliance infrastructure. Buying a validated brand can be faster and less risky than building one internally.

The problem begins when that model is treated as universal. Consumer venture capital rewards rapid SKU expansion, revenue growth, digital acquisition and liquidity within a fund-defined period. Clinical nutrition rewards narrower indications, longer research cycles, conservative claims, medical affairs, publication, independent replication and professional trust accumulated over years. Applying consumer-brand milestones to an oncology-nutrition company can force premature portfolio expansion and chronic underinvestment in evidence.

THE RIGHT CAPITAL QUESTION

The relevant choice is not VC versus no VC. It is whether the source, structure and patience of the capital match the company's evidence cycle and category-building period.

Several alternative routes are already visible. HealthKart has used growth equity, private equity, secondary liquidity and profitable scale without immediately selling to a conglomerate. Hexagon Nutrition built a full-stack nutrition company before accessing public markets. Kapiva has articulated an innovation and pre-IPO path. Cosmix was reportedly bootstrapped and profitable before selling a controlling interest. Organic India spent more than two decades building farmer networks, international distribution and category trust before becoming part of Tata Consumer.

A strategic sale is therefore not proof that a founder lacked ambition. Nor is continued independence proof of legacy. The decisive issue is what exists before and after the transaction. A company that has built science, sourcing systems, professional trust and governance may preserve its institutional value under new ownership. A company built mainly on advertising arbitrage may disappear into a portfolio as soon as growth slows.

Business architecture	Best-aligned capital	Plausible long-term outcome
Broad D2C wellness brand	Consumer VC and strategic capital	Acquisition, brand roll-up or strategic subsidiary
Omnichannel house of brands	Growth equity and private equity	Secondary liquidity, consolidation or IPO
Clinical or FSMP company	Healthcare funds, family offices, grants, hospital and pharma partnerships	Independent specialist, licensing platform or healthcare strategic transaction
Proprietary ingredient platform	Strategic R&D capital, B2B partnerships and export finance	Licensing, royalties, ingredient exports or acquisition
Mature full-stack nutrition institution	Private equity and public markets	Listed independent company with durable governance

Who is actually investing in clinical evidence?

Publicly visible evidence across Indian supplement startups remains uneven. Some companies are beginning to fund trials, but ingredient citations, patents and consumer testimonials are still frequently presented as though they were equivalent to finished-product efficacy. They are not.

The Good Bug

The Good Bug has one of the stronger publicly visible trial signals among newer consumer-health startups: a registered, randomised, double-blind, placebo-controlled, multicentre 90-day study of a probiotic-fibre blend. That design is materially stronger than the category norm. The reported effect size, short duration, sponsor funding, lifestyle counselling and multi-ingredient formulation nevertheless make independent replication and longer follow-up essential before broad conclusions are drawn.

Nutrova
Nutrova has shown comparatively disciplined transparency through a registered, peer-reviewed study of a collagen-anti-oxidant product in a small group of Indian women. The work is useful and more credible than unsupported marketing, but the sample size and design do not provide the certainty of a large parallel, randomised and blinded trial. Its significance lies as much in the company's reporting discipline as in the result itself.

Kapiva
Kapiva has published early open-label work in metabolic health and has announced an innovation fund of up to Rs 50 crore for formulation science, phytochemical standardisation, extraction, bioavailability, preclinical research and clinical studies. The intent is strategically important. The current public evidence, however, is still early-stage and does not yet match the scale of the ambition.

Gynoveda
Gynoveda reports prospective and retrospective work in PCOS and fertility-related use cases. Such studies can provide useful real-world signals and help refine hypotheses, but open-label and retrospective designs have important limitations. They are not substitutes for independent controlled trials when a company is making strong causal claims.

Esperer Nutrition
Esperer has developed patent activity around cancer-patient nutrition and has associated small post-marketing studies with parts of its portfolio. These are meaningful signs of category intent, but patents establish novelty claims rather than clinical efficacy, and small uncontrolled surveillance studies are hypothesis-generating rather than definitive. Esperer's next step must be independent outcome evidence.

The broader conclusion is uncomfortable but important: no Indian supplement startup reviewed here has yet established an unquestionable top evidence tier based on independent, preregistered, adequately powered, multicentre trials with clinically meaningful endpoints and external replication. The sector is progressing, but it is still early.

EVIDENCE RULE
A product containing clinically studied ingredients is not the same as a finished product that has demonstrated its claimed outcome at the marketed dose, in the marketed formulation, in the intended population.

The Esperer test: genuine category creation or an unproven thesis?

Esperer Nutrition deserves special attention because it has chosen one of the hardest routes in the market: nutrition for people undergoing cancer treatment and for other medically managed conditions. This is fundamentally different from launching another beauty gummy. The decision-maker is not only the consumer. It may also be the oncologist, dietitian, hospital, caregiver, pharmaceutical partner or institutional buyer.

What Esperer is doing correctly
First, it is starting with a clinically important problem. Cancer patients can experience appetite loss, weight loss, muscle depletion, treatment intolerance and prolonged recovery. A condition-specific platform is more relevant than a generic high-protein powder.

Second, it has created stage-specific portfolio architecture rather than treating oncology nutrition as a single homogeneous need. That can support deeper protocols and clearer professional use cases.

Third, it is attempting to build through intellectual property and healthcare-professional channels. Patent activity and an oncology-oriented product system signal an intention to own formulation architecture and professional trust, even though neither is yet equivalent to proven clinical outcomes.

What Esperer must prove next

- Run indication-specific, multicentre trials in clearly defined cancer types and treatment pathways rather than heterogeneous all-cancer populations.
- Use independent principal investigators, preregistration, external statistics and transparent publication of both positive and negative findings.
- Measure lean mass, weight stability, treatment interruptions, chemotherapy dose intensity, adverse events, hospital days, functional status and quality of life - not only appetite or subjective wellbeing.
- Build health-economic evidence showing whether nutritional intervention reduces complications, hospitalisation, treatment abandonment or total cost of care.
- Treat taste, gastrointestinal tolerance, caregiver education and adherence tracking as core clinical-product design, not secondary packaging questions.
- Develop hospital and pharmaceutical partnerships that provide patient access, medical-affairs credibility, co-development capacity and better-aligned capital.

Esperer should therefore not be financed or managed like a beauty-supplement company. The better sources of capital are healthcare-focused funds, patient family offices, research grants, hospital partnerships, pharmaceutical co-development and milestone-based strategic funding. The value inflection will come less from adding more SKUs and more from generating independent outcome data and embedding products into care pathways.

The judgement is balanced: Esperer is one of the few emerging Indian companies attempting authentic category construction in oncology nutrition, and its category thesis is stronger than its current public evidence base. That is not a dismissal. It is a description of the work that must now be done.

Seven tests for founders, investors and strategic buyers

- Is the evidence on the finished product, or only on individual ingredients used elsewhere and at different doses?
- What proportion of revenue comes from repeat customers without deep discounting, affiliates or unsustainably high paid-media spend?
- Does the company have a credible route beyond direct-to-consumer acquisition into retail, pharmacies, practitioners, hospitals or institutions?
- Are the claims supportable under the current FSSAI framework, and is there a complete product-specific substantiation dossier?
- Does the capital structure match the product's research cycle, or will investors force premature scaling and excessive SKU proliferation?
- Is the company building proprietary formulations, longitudinal data, professional trust, manufacturing capability or defendable sourcing assets?
- What will remain valuable if the founder, celebrity endorsements, packaging and current social-media channels are removed from the equation?

Who is building a legacy?

Legacy is often confused with founder ownership or avoidance of an exit. A legacy company is better defined by the assets that can survive the founder, the current packaging and the advertising cycle: reproducible science, intellectual property, quality systems, professional trust, long-term sourcing networks, longitudinal data, profitable economics, governance and management depth.

Company	What could endure	Principal gap	Present judgement
HealthKart	Scale, a portfolio of recognised brands, omnichannel distribution and demonstrated commercial economics.	Its most visible moat remains commercial rather than clinical.	The strongest independent commercial institution among the newer companies.
Hexagon Nutrition	Premixes, clinical brands, therapeutic nutrition, exports, institutional customers and public-market discipline.	Less culturally visible than fashionable D2C brands.	The clearest Indian benchmark for a durable full-stack nutrition institution.
Organic India	Long brand history, global reach, sourcing relationships and farmer networks built before acquisition.	Its future mission now depends partly on Tata Consumer's stewardship.	A legacy was already present before the transaction.
Kapiva	Ayurveda modernisation, distribution and a stated commitment to standardisation and research.	High-grade finished-product evidence remains limited.	One of the strongest science-building ambitions in modern Ayurveda; execution is still being tested.
The Good Bug	Microbiome category education, a programme model and a visible controlled trial.	Replication, long-term durability and strain-specific differentiation.	An emerging evidence-led consumer-health platform.
Nutrova	Transparency, third-party testing and a willingness to publish product-level evidence.	Limited scale and modest study designs.	A small but disciplined evidence-first builder.
Esperer Nutrition	Condition-specific portfolio, oncology focus, professional orientation and IP intent.	Independent trials, health economics and broader hospital adoption.	A credible category-creation attempt whose legacy remains to be earned.

OZiva, Wellbeing Nutrition and Plix have built meaningful franchise value and achieved strong strategic outcomes. Whether they become enduring health institutions now depends on what their owners do next: invest in evidence, formulations, manufacturing and category standards, or treat the brands primarily as high-growth components of broader portfolios. Ownership is not the decisive variable. Institutional assets are.

The next Indian nutrition champion will be harder to build

India will continue to create successful FMCG-style supplement brands. Many will grow through need-state positioning, attractive formats and omnichannel distribution; some will be acquired, and those outcomes can be entirely rational. But the first globally respected, evidence-led Indian nutrition institution is unlikely to emerge from the next flavour, gummy or influencer campaign.

It is more likely to emerge from clinical depth, proprietary data, disciplined claims, patient capital and a willingness to build slowly where the barriers are highest. The strategic question for the sector is therefore changing. It is no longer simply, 'Can India sell more supplements?' It is, 'Can India produce reproducible outcomes, earn professional trust and create nutrition institutions whose value compounds for decades?'

PEOPLE BUILD THE PLANT

HR Management Insights from Building a Large Indian CDMO

RANI GARG

Whole-Time Director, Zeon Lifesciences Limited

When people look at a large contract development and manufacturing organisation, they usually see sophisticated plants, production lines, laboratories, certifications and capacity. I see something more fundamental: people making thousands of correct decisions every day. A CDMO grows only when operators, scientists, quality professionals, engineers, supply-chain teams and business leaders work with the same discipline and purpose. The journey of Zeon Lifesciences has taught me that Human Resources is not merely a support function. It is an essential part of the manufacturing system, the quality system and the customer promise.

Our entrepreneurial journey began in Paonta Sahib with dairy manufacturing and later evolved into nutraceutical and Ayurvedic manufacturing. Over the years, Zeon expanded its capabilities, product formats, scientific expertise and market reach. Suresh Garg brought vision, persistence and the courage to build for the long term. My responsibility was to focus on people, talent, organisational relationships and culture. This complementary partnership became an important management lesson: sustainable scale requires both strategic ambition and careful stewardship of people.

The first HR learning is to hire for character as seriously as competence. Technical knowledge is essential in a regulated industry, but integrity, learning agility and respect for process determine how that knowledge is applied. A technically brilliant employee who bypasses documentation, ignores safety or treats quality as someone else's responsibility creates risk. Recruitment must therefore assess behaviour as well as qualifications. Structured interviews, functional evaluations and practical discussions about deviations, pressure, ambiguity and ethical choices help identify people who can be trusted with responsibility.

The second learning is that quality must become a people habit. Training cannot be limited to induction or an annual compliance calendar. Every role should have a defined skill matrix, supervised qualification, periodic reassessment and clear accountability. Employees must understand not only what a standard operating procedure requires, but why it matters to the customer and the consumer. HR should work closely with Quality, Operations, R&D and Regulatory teams to measure time to competency, right-first-time performance, recurring deviations, training effectiveness, audit readiness and internal readiness for critical positions. These indicators connect people practices directly with business reliability.

The third learning is that growth demands professionalisation without losing the founder's purpose. As product categories, technologies, markets and regulations expand, the organisation must bring in experienced specialists, clarify decision rights and allow expertise to operate. The HR function must build a leadership bench rather than depend on a few individual heroes. Succession planning, cross-functional exposure, mentoring and second-line development protect continuity and reduce organisational risk.

At each stage of expansion, HR must translate the business plan into a workforce plan. Which capabilities are scarce? Which roles can be developed internally? Where is external expertise essential? How quickly must teams become productive? Expansion without this discipline may create impressive infrastructure that the organisation cannot use consistently or efficiently.

The fourth learning is that employees need meaning as well as employment. A company associated with health and nutrition must reflect those values internally through safety, dignity, fairness and development. Capability-building programmes, workplace safety, prevention of harassment, employee recognition, sports, celebrations and community initiatives all strengthen belonging. However, engagement activities cannot substitute for sound management. People also need clear goals, fair performance reviews, competitive rewards, career pathways and managers who provide timely feedback. A caring culture becomes credible only when systems are transparent and decisions are consistent.

The fifth learning is that inclusion expands organisational intelligence. Workplace equality cannot remain a ceremonial statement. Women must receive access to technical roles, plant leadership, development assignments and decision-making forums. Managers must recognise different life stages and create practical support without lowering performance standards. Empathetic leadership improves listening and collaboration, but empathy must lead to action: safer workplaces, unbiased selection, equitable development and the confidence to speak up.

The sixth learning is that a manufacturing company must invest in its wider talent ecosystem. Recruitment alone cannot solve long-term capability gaps. Partnerships with educational institutions, apprenticeships, local skill development and community support create a stronger talent pipeline while building social trust. Employability begins well before a vacancy is announced, and responsible organisations must contribute to preparing future generations for meaningful work.

Finally, HR must remain close to the shop floor and close to the customer. Leaders should listen to operators, understand shift realities and examine why errors, delays or fatigue occur. Employees must also understand that a CDMO protects its clients' formulations, timelines, reputation and consumers. Confidentiality, responsiveness and scientific rigour are therefore cultural competencies, not merely contractual requirements.

The deepest lesson from Zeon's journey is simple: machines create capacity, but people create reliability. Sustainable scale comes from combining entrepreneurial courage with capable teams, disciplined systems, inclusive leadership and continuous learning. When HR measures its contribution through quality, capability, trust and customer outcomes, it becomes one of the strongest engines for building a globally respected Indian CDMO.

Green
SPACE HERBS

Quantum
Ayurveda

BerberineQA™

Metabolic balance- frequency aligned Berberine

Greenspace Herbs delivers clinically validated **Energized Active Supplement Ingredients (EASI)™** by leveraging AI, Quantum Chemistry & Ayurveda.

Clinical Insights:

- **4× higher bioavailability** than standard berberine
- **18× higher Cmax with Tmax of 2.5 hours,** indicating faster and stronger absorption
- **Longer half-life,** suggesting prolonged effect compared to standard berberine

Blood Sugar Support | Anti-Inflammatory | Weight Management

quantum@greenspaceherbs.com www.greenspaceherbs.com

Corporate Office: Unit No. 0401N, 4th Floor, Beacon Tower-2, BRIGADE TWIN TOWERS, No.11/1-4, Jai Bharath Industries Pipeline Road, Yeshwanthpur, Bengaluru-560 022.

THE RELEVANCE OF CLINICAL EVIDENCE IN NUTRACEUTICAL FORMULATIONS: BRIDGING THE GAP BETWEEN SCIENCE AND CONSUMER TRUST

Praneeth Immadisetti, Nutrition Scientist III, Nutrition Science & Clinical Research – R&D, Dr. Reddy's Laboratories Limited

Nutraceuticals are biologically active substances, which contributes in maintaining optimal health and provides health benefits. They are often described as specially designed preparations, formulated to meet defined dietary and nutritional requirements. These products play an increasingly important role in human healthcare and are expected to contribute significantly to future advancements in preventive and supportive health solutions.

Over the past decade, the nutraceutical and food supplement industry has experienced remarkable growth, largely driven by rising consumer awareness around preventive healthcare, healthy aging, sports nutrition, and personalized wellness. However, one of the key challenges in nutraceutical development lies in translating scientific discoveries into meaningful, credible, and consumer-relevant health benefits. Clinical evidence serves as a critical bridge between laboratory research and real-world application.

Why Clinical Evidence Matters?

Clinical evidence plays a pivotal role in substantiating the proposed biological effects of nutraceutical ingredients and finished formulations. It enables the transition from hypothesized mechanisms of action, primarily derived from in-vitro experiments and animal models, to validated outcomes in human populations. Well-designed clinical studies help supports the establishment of a cause-and-effect relationship between product consumption and intended health outcomes.

This is particularly important for multi-ingredient nutraceutical formulations. Although individual bioactive components may be supported by existing scientific literature, their efficacy within a finished formulation requires independent validation. Factors such as ingredient compatibility, synergistic or antagonistic interactions, dosage, bioavailability, stability, manufacturing processes, and matrix effects may significantly influence the biological performance of the final product. Therefore, clinical evaluation of the complete formulation is essential to confirm that the product delivers the intended physiological or health benefits under conditions of actual consumption.

Robust clinical substantiation can reduce scientific and commercial uncertainty during product development and commercialization. It also strengthens product credibility among healthcare professionals, regulatory stakeholders, and consumers.

Furthermore, clinical research is central to advancing innovation in the nutraceutical sector, particularly for emerging ingredient categories such as postbiotics, synbiotics, plant-derived bioactives, liposomal nutrients, bioactive peptides, and precision nutrition-based interventions. These novel approaches require rigorous scientific validation to establish safety, tolerability, efficacy, and clinical relevance.

Conceptual Understanding of Clinical Evidence

Clinical evidence refers to scientifically generated data obtained from studies conducted in human participants to evaluate the safety, efficacy, tolerability, and potential health benefits of a specific ingredient, formulation, or nutritional intervention. Compared with in-vitro and animal studies, human clinical trials provide a higher level of translational relevance, as they assess product performance under real physiological and behavioral conditions.

Among the different forms of clinical research, randomized controlled trials, systematic reviews, and meta-analyses are generally regarded as high-quality sources of evidence. Randomized controlled trials are particularly important for evaluating intervention-related outcomes, while systematic reviews and meta-analyses provide an integrated assessment of the available evidence base.

Regulatory authorities, scientific bodies, and expert panels frequently consider well-designed human intervention studies when evaluating the scientific substantiation of health-related claims and product efficacy.

Overall, clinical evidence is fundamental to evidence-based nutraceutical development. It supports scientific validation, enhances regulatory and professional acceptance, guides formulation optimization, and helps bridge the gap between experimental research and meaningful health outcomes in target consumer populations.



Fig 1: The hierarchy (levels) of evidence (in descending order of evidence strength).

Role of Clinical Evidence:
A) Demonstrates Product Efficacy
B) Establishes Safety and Tolerability
C) Enables Evidence-Based Claim Development
D) Facilitates Regulatory review and approval frameworks
E) Provides Confidence and insights to Health Care Professionals
F) Enhances Consumer Trust

Key Considerations in the Design of Clinical Trials:

Epidemiological evaluation of scientific evidence is fundamental to determining whether a given exposure or intervention is causally associated with a specific health outcome. In this context, study designs are generally positioned within a hierarchy of evidence, based on their methodological rigor, ability to minimize bias, and strength in supporting causal inference.

Clinical trials are prospective, planned experimental studies designed to evaluate the efficacy and/or safety of an intervention by assessing predefined outcomes in a group of participants. Typically, these outcomes are compared with those observed in a comparable control group receiving either placebo, standard care, or an alternative intervention. The robustness of a clinical trial largely depends on appropriate study design, participant selection, intervention characteristics, comparator selection, outcome measures, statistical power, and control of potential confounding factors.

Sample Size, Statistical Power, and Effect Size

Adequate sample size and statistical power are critical to the validity and reliability of clinical trial findings. Underpowered studies reduce the likelihood of detecting true intervention effects and may increase the risk of false-negative results or overestimated statistically significant findings.

Therefore, sample size estimation should be based on predefined assumptions, including expected effect size, variability, significance level, and desired power.

Effect size represents the magnitude of difference or association between intervention and control groups and is central to both trial design and interpretation. Smaller anticipated effect sizes require larger sample sizes to detect clinically meaningful differences. Hence, accurate effect size estimation is essential to ensure adequate study power, meaningful interpretation, and alignment with the primary research objective.

Conclusion:

In conclusion, clinical studies help identify - Optimal dosage, Target populations, Benefit endpoints, Biomarker improvements, Safety parameters & Comparative performance versus standard formulations etc., Such evidence drives continuous innovation while ensuring scientific credibility. Most importantly, clinical evidence bridges multiple critical gaps between laboratory science and human health outcomes, between product innovation and regulatory requirements, and between consumer expectations and actual product performance.

WHY OPERATIONAL INTELLIGENCE IS CHANGING GLOBAL COMMERCE LESSONS FROM HELPING 150+ BRANDS SCALE INTERNATIONALLY

Global commerce has never been more accessible, yet scaling internationally remains one of the biggest challenges for growing brands. The opportunity is undeniable. The global wellness economy is now valued at $6.8 trillion, creating significant growth potential for nutraceutical and wellness brands looking beyond their domestic markets. But market access alone is no longer enough. Sustainable global growth depends on making the right decisions before entering a market—and executing them consistently thereafter.

The biggest barriers to international expansion are rarely product-related. In our experience supporting 150+ brands across 20+ countries and 25+ ecommerce channels, we've found that businesses often struggle because they enter new markets without enough intelligence. They lack visibility into consumer demand, regional buying behaviour, competitive dynamics, pricing expectations, and the channels that will drive the strongest returns. These decisions are frequently made using fragmented data or assumptions rather than actionable insights.

The cost of getting these decisions wrong is significant. Choosing the wrong market, launching with the wrong assortment, or misjudging demand can lead to excess inventory, inefficient marketing spend, compliance challenges, and slower growth. By the time these issues become visible, businesses have already invested substantial time and resources.

This is where operational intelligence becomes a competitive advantage. It goes beyond automation or artificial intelligence. It combines market intelligence, demand forecasting, compliance, inventory planning, supply chain visibility, fulfilment, and marketplace performance into a connected operating model. When every part of the business works from the same source of truth, leaders can make faster, more informed decisions and adapt quickly as markets evolve.

We've seen the impact of this firsthand. Across the brands we've supported, we've enabled more than $1 billion in global GMV, while helping businesses reduce the time spent gathering insights and reporting by 75% through connected operational visibility. The result is that teams spend less time managing complexity and more time driving growth.

This shift is especially important for India's rapidly growing nutraceutical sector. Product innovation continues to accelerate, but global success increasingly depends on understanding where demand exists, what consumers are looking for, which certifications influence purchasing decisions, and how to build resilient operations across markets.

The future of global commerce will not be defined by innovation alone. It will belong to businesses that combine great products with better intelligence, connected operations, and the ability to make confident decisions at scale. In a world where complexity is only increasing, operational intelligence is no longer a competitive advantage—it is becoming the foundation of sustainable global growth.

SOMDUTTA SINGH
Founder & CEO, Assiduus Global



Fetaari™

Fetaari is a science-driven female wellness formula combining Shatavari, fenugreek saponins, and Calcium Chloride engineered to support hormonal balance, energy, mood, and overall vitality.

Shatavarins
(Asparagus racemosus)

- Contains Total saponins (Shatavarins) that act as phytoestrogens.
- **Shatavarin-4** is a key estrogen-modulating saponin, that supports hormonal balance, reproductive health & PCOS management.
- Supports estrogen modulation—useful in irregular cycles, PMS, perimenopause, and menopause.
- Improves insulin sensitivity, reduces cortisol levels and protects body from oxidative stress.

Fenugreek Extract
(80% Saponins)

- Healthy estrogen modulation
- Improved female reproductive health
- Better PMS comfort, mood, and energy

Calcium Chloride

- Supports bone density, neuromuscular function, hydration balance, and premenstrual syndrome (PMS) symptom relief.

Why Choose Fetaari?

- **Holistic Support for Women**– empowers women with a natural blend that supports hormonal harmony, stress relief, and lifelong reproductive wellness.
- **Science-backed Herbal Formula**– A unique blend of Shatavari and Fenugreek, each supported by research for women's hormonal balance and metabolic health.
- **Extra Nutrient Support**– Calcium chloride for bone density and healthy reproductive function.

Fetaari
Core benefits

- Hormonal balance
- Energy
- Mood support

From Lab to Life, Globally

Empowering Brand . Elevating Science

EPISODE 8

THE R&D GRAIL SHOW

Pre/Pro/Syn/Postbiotics: From Alchemy to science-backed solutions for overall gut health

31 JULY 2026 | 4PM - 5PM

BROUGHT TO YOU BY

Arjuna Natural

KNOWLEDGE PARTNER

D Y PATIL DEEMED TO BE UNIVERSITY SCHOOL OF PHARMACY NAVI MUMBAI

Register: https://nutrifytoday.live/The-Grail

nutrify today®

ACADEMY®
Nutra Upskill Partner

GET INSIGHTS OF ONGOING TRENDS IN NUTRACEUTICALS AND INNOVATIONS AND WORK TOWARDS ACHIEVING A COMPETITIVE ADVANTAGE IN NUTRACEUTICAL INDUSTRY. LEARN FROM GLOBAL LEADERS AND EXPERTS FROM THE INDUSTRY.

Duration: 3 months

For the First 50 Registrations

Full Course: Rs. 2499

Single Module: Rs. 2499

1 Short Video: Rs. 2499

OTC MARKETING MANAGEMENT	NEW PRODUCT DEVELOPMENT & COMMERCIALIZATION	APPLIED PSYCHOBIOTICS – A NEW PROMISE IN NEUROPSYCHIATRY
INDIAN REGULATORY SYSTEM	APPLIED PROBIOTICS FOR FOOD TECHNOLOGY & PHARMACEUTICALS	PLANT AUDIT AND PRODUCT REGISTRATION IN NUTRACEUTICALS
PROCESS VALIDATION IN NUTRACEUTICALS	NUTRACEUTICALS FOR NUTRITIONISTS AND DIETITIANS	NUTRACEUTICALS: CHEMISTRY, CLINICAL STUDIES AND PROCESSES

REGISTER NOW



https://academy.nutrifytoday.com/ +919538011662

Download app now: “nutrifytoday”



For any business enquiries, please write to us: hello@nutrifytoday.com

Contact our team

Speaking/ Partnership/Delegate Opportunity

Akansha Kuriyal

akansha@nutrifytoday.com

+91 98331 96127

Khasim M

khasim@nutrifytoday.com

+91 99715 72969

https://nutrifycsuite.com/